Accelerated TMS treatment, applied to both sides of the brain, shows significant results in rapidly alleviating depression symptoms.
Recent advancements in transcranial magnetic stimulation (TMS) are reshaping treatment paths for patients suffering from treatment-resistant depression. A recent study indicates that a method applying magnetic fields to both sides of the brain can yield rapid improvements, especially in severe cases where traditional approaches have faltered.
TMS utilizes an electromagnetic coil placed on the scalp to send targeted magnetic pulses into the brain. Specifically, the therapy works by addressing activity imbalances in key areas implicated in depression, like the dorsolateral prefrontal cortex (DLPFC) and the orbitofrontal cortex (OFC). Although TMS targeting the left DLPFC is approved for use in the UK and US, its longer treatment timeline—typically spanning 20 sessions over several weeks—poses challenges for acute scenarios, including suicidal patients.
Research detailed in Psychological Medicine tested an accelerated regime of TMS involving multiple sessions per day over a condensed period. Scientists from the University of Cambridge and the Guizhou Mental Health Centre in China conducted the trial, emphasizing a dual stimulation approach that tackles the left DLPFC alongside the right OFC.
Study Design and Results
Seventy-five participants, identified as experiencing major depressive disorder, were randomly allocated into three distinct groups for the study. One group received dual TMS targeting both brain regions, while another group underwent sham treatment on the right side followed by active treatment on the left. A control group received placebos with no active stimulation. Each treatment session lasted 22 minutes.
Results demonstrated notable effectiveness in the dual treatment group. After completing the protocol, nearly half of the participants (48%) showcased significant reductions in their depression scores, defined as at least a 50% improvement. In contrast, only 18% in the single treatment group and a mere 4% in the control group achieved similar outcomes.
Four weeks post-treatment, about 61% of the dual group and 59% of the single treatment group maintained these clinically relevant improvements, compared to just 22% in the control cohort.
Significance of Dual Stimulation
Leading the research effort, Professor Valerie Voon from the University of Cambridge highlighted the accelerated method's potential to deliver rapid results for severely depressed individuals, potentially allowing for quicker hospital discharges and even a preventative tool against hospitalization. The dual-target approach aims to rectify the communication breakdown between the DLPFC and OFC, which is vital for decision-making related to rewards and punishments—processes often skewed in individuals with depression.
The findings also shed light on the correlation between effective treatment and the initial connectivity between the OFC and thalamus. This area of the brain plays a crucial role in consciousness, sleep, and alertness, impacting how patients respond to stimuli and rewards.
Optimism for Treatment-Resistant Cases
Dr. Yanping Shu from Guizhou Mental Health Centre noted the results' implications for treatment-resistant depression, stating that patients reported feeling "lighter and brighter" soon into the treatment. The rapid improvements noted suggest a positive shift in the treatment paradigm for those predominantly affected by chronic and severe depressive episodes.
However, it’s critical to acknowledge that the dual TMS approach resulted in some reports of localized pain from participants, yet this didn’t lead to any discontinuations in the study. For some individuals, a single course of TMS might suffice, while maintenance therapy could be beneficial for others to prevent symptom resurgence.
Future research is planned to pinpoint the most effective targets within the OFC and to determine the specific profiles of depression that this dual approach may best serve. Advancements here could carve out new avenues for holistic mental health care.
As researchers continue to explore these approaches, parallel options like transcranial direct current stimulation are also being considered, offering further potential avenues for home-based treatment options post-initial therapy.
This research was supported by both the Medical Research Council in the UK and the National Institute for Health and Care Research at the Cambridge Biomedical Research Centre. Such collaborations underscore the urgent need for effective interventions in a field that has consistently faced challenges in treating resistant depression.
Materials provided by University of Cambridge under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Discussion
Sign in to join the discussion.